Does the media favor SLDB or CGEN?

In the previous week, Compugen had 2 more articles in the media than Solid Biosciences. MarketBeat recorded 5 mentions for Compugen and 3 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.58 beat Compugen's score of 0.50 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Compugen 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CGEN or WVE?

In the previous week, WAVE Life Sciences had 11 more articles in the media than Compugen. MarketBeat recorded 16 mentions for WAVE Life Sciences and 5 mentions for Compugen. Compugen's average media sentiment score of 0.50 beat WAVE Life Sciences' score of -0.09 indicating that Compugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive WAVE Life Sciences 0 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to CGEN or IMMX?

In the previous week, Compugen had 3 more articles in the media than Immix Biopharma. MarketBeat recorded 5 mentions for Compugen and 2 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.15 beat Compugen's score of 0.50 indicating that Immix Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immix Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CGEN or OLMA?

In the previous week, Compugen had 1 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 5 mentions for Compugen and 4 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.73 beat Compugen's score of 0.50 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Olema Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CGEN or RIGL?

In the previous week, Compugen had 1 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 5 mentions for Compugen and 4 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.80 beat Compugen's score of 0.50 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rigel Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Compugen (CGEN) Competitors

$2.37 +0.03 (+1.28%)

Closing price 04:00 PM Eastern

Extended Trading

$2.35 -0.02 (-1.05%)

As of 07:30 PM Eastern

Compare

CGEN vs. SLDB, WVE, IMMX, OLMA, and RIGL

Should you buy Compugen stock or one of its competitors? Compugen's main competitors and comparable companies include Solid Biosciences (SLDB), WAVE Life Sciences (WVE), Immix Biopharma (IMMX), Olema Pharmaceuticals (OLMA), and Rigel Pharmaceuticals (RIGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Compugen compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Compugen (NASDAQ:CGEN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Compugen has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A
Compugen	$72.76M	3.08	$35.34M	$0.38	6.24

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 12.2% of Compugen shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by insiders. Comparatively, 9.5% of Compugen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Solid Biosciences currently has a consensus price target of $18.69, suggesting a potential upside of 149.90%. Compugen has a consensus price target of $5.00, suggesting a potential upside of 110.97%. Given Solid Biosciences' higher possible upside, equities analysts plainly believe Solid Biosciences is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Compugen	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Solid Biosciences has a beta of 2.44, suggesting that its stock price is 144% more volatile than the broader market. Comparatively, Compugen has a beta of 2.78, suggesting that its stock price is 178% more volatile than the broader market.

In the previous week, Compugen had 2 more articles in the media than Solid Biosciences. MarketBeat recorded 5 mentions for Compugen and 3 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.58 beat Compugen's score of 0.50 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Compugen	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Compugen has a net margin of 47.56% compared to Solid Biosciences' net margin of 0.00%. Compugen's return on equity of 42.57% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-71.35%	-60.58%
Compugen	47.56%	42.57%	26.13%

Summary

Compugen beats Solid Biosciences on 12 of the 16 factors compared between the two stocks.

How does Compugen compare to WAVE Life Sciences?

Compugen (NASDAQ:CGEN) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

In the previous week, WAVE Life Sciences had 11 more articles in the media than Compugen. MarketBeat recorded 16 mentions for WAVE Life Sciences and 5 mentions for Compugen. Compugen's average media sentiment score of 0.50 beat WAVE Life Sciences' score of -0.09 indicating that Compugen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	0 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Compugen has a beta of 2.78, indicating that its stock price is 178% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.3, indicating that its stock price is 230% less volatile than the broader market.

Compugen has higher revenue and earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	3.08	$35.34M	$0.38	6.24
WAVE Life Sciences	$42.73M	18.26	-$204.38M	-$1.09	N/A

12.2% of Compugen shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 9.5% of Compugen shares are held by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Compugen has a net margin of 47.56% compared to WAVE Life Sciences' net margin of -309.73%. Compugen's return on equity of 42.57% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.56%	42.57%	26.13%
WAVE Life Sciences	-309.73%	-50.36%	-40.06%

Compugen presently has a consensus target price of $5.00, indicating a potential upside of 110.97%. WAVE Life Sciences has a consensus target price of $22.31, indicating a potential upside of 463.45%. Given WAVE Life Sciences' higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
WAVE Life Sciences	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

Summary

Compugen beats WAVE Life Sciences on 11 of the 17 factors compared between the two stocks.

How does Compugen compare to Immix Biopharma?

Compugen (NASDAQ:CGEN) and Immix Biopharma (NASDAQ:IMMX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

12.2% of Compugen shares are held by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are held by institutional investors. 9.5% of Compugen shares are held by company insiders. Comparatively, 30.3% of Immix Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Compugen currently has a consensus price target of $5.00, indicating a potential upside of 110.97%. Immix Biopharma has a consensus price target of $22.86, indicating a potential upside of 95.36%. Given Compugen's stronger consensus rating and higher possible upside, research analysts plainly believe Compugen is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Compugen has a beta of 2.78, indicating that its stock price is 178% more volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market.

Compugen has a net margin of 47.56% compared to Immix Biopharma's net margin of 0.00%. Compugen's return on equity of 42.57% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.56%	42.57%	26.13%
Immix Biopharma	N/A	-38.44%	-34.72%

Compugen has higher revenue and earnings than Immix Biopharma. Immix Biopharma is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	3.08	$35.34M	$0.38	6.24
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A

In the previous week, Compugen had 3 more articles in the media than Immix Biopharma. MarketBeat recorded 5 mentions for Compugen and 2 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.15 beat Compugen's score of 0.50 indicating that Immix Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immix Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Compugen beats Immix Biopharma on 13 of the 16 factors compared between the two stocks.

How does Compugen compare to Olema Pharmaceuticals?

Compugen (NASDAQ:CGEN) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

Compugen has a net margin of 47.56% compared to Olema Pharmaceuticals' net margin of 0.00%. Compugen's return on equity of 42.57% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.56%	42.57%	26.13%
Olema Pharmaceuticals	N/A	-48.26%	-43.04%

In the previous week, Compugen had 1 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 5 mentions for Compugen and 4 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 0.73 beat Compugen's score of 0.50 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Olema Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Compugen has a beta of 2.78, suggesting that its stock price is 178% more volatile than the broader market. Comparatively, Olema Pharmaceuticals has a beta of 1.98, suggesting that its stock price is 98% more volatile than the broader market.

Compugen has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	3.08	$35.34M	$0.38	6.24
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A

Compugen presently has a consensus target price of $5.00, indicating a potential upside of 110.97%. Olema Pharmaceuticals has a consensus target price of $40.60, indicating a potential upside of 349.12%. Given Olema Pharmaceuticals' higher probable upside, analysts clearly believe Olema Pharmaceuticals is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Olema Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

12.2% of Compugen shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 12.6% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Compugen beats Olema Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Compugen compare to Rigel Pharmaceuticals?

Compugen (NASDAQ:CGEN) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

Compugen has a beta of 2.78, meaning that its stock price is 178% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Compugen currently has a consensus target price of $5.00, suggesting a potential upside of 110.97%. Rigel Pharmaceuticals has a consensus target price of $59.00, suggesting a potential upside of 23.20%. Given Compugen's stronger consensus rating and higher possible upside, equities research analysts clearly believe Compugen is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Rigel Pharmaceuticals has a net margin of 116.30% compared to Compugen's net margin of 47.56%. Compugen's return on equity of 42.57% beat Rigel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.56%	42.57%	26.13%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

12.2% of Compugen shares are owned by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 9.5% of Compugen shares are owned by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Compugen had 1 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 5 mentions for Compugen and 4 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.80 beat Compugen's score of 0.50 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rigel Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rigel Pharmaceuticals has higher revenue and earnings than Compugen. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	3.08	$35.34M	$0.38	6.24
Rigel Pharmaceuticals	$294.28M	3.01	$367.02M	$16.32	2.93

Summary

Compugen beats Rigel Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Compugen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGEN vs. The Competition

Export

Metric	Compugen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$235.44M	$3.98B	$7.33B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	6.24	8.31	214.34	21.27
Price / Sales	3.08	1,346.23	639.66	87.10
Price / Cash	6.66	113.29	77.80	52.76
Price / Book	2.17	15.46	10.52	6.34
Net Income	$35.34M	-$22.82M	$3.49B	$360.00M
7 Day Performance	-3.66%	-2.21%	-1.08%	-0.11%
1 Month Performance	-8.49%	-6.66%	-3.39%	-3.42%
1 Year Performance	69.29%	30.99%	15.08%	5.46%

Compugen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGEN Compugen	3.5525 of 5 stars	$2.37 +1.3%	$5.00 +111.0%	+63.6%	$235.44M	$72.76M	6.24	75	News Coverage
SLDB Solid Biosciences	2.1215 of 5 stars	$8.32 -4.8%	$18.75 +125.4%	+50.5%	$891.96M	N/A	N/A	121
WVE WAVE Life Sciences	2.6794 of 5 stars	$4.52 -1.4%	$22.31 +394.2%	-42.2%	$889.68M	$42.73M	N/A	317	Trending News Analyst Forecast
IMMX Immix Biopharma	3.2865 of 5 stars	$12.00 -1.8%	$22.86 +90.6%	+481.5%	$857.75M	N/A	N/A	21	Positive News
OLMA Olema Pharmaceuticals	2.6776 of 5 stars	$9.77 -5.1%	$40.60 +315.8%	+0.5%	$855.03M	N/A	N/A	150	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGEN) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compugen (CGEN) Competitors

CGEN vs. SLDB, WVE, IMMX, OLMA, and RIGL

How does Compugen compare to Solid Biosciences?

Summary

How does Compugen compare to WAVE Life Sciences?

Summary

How does Compugen compare to Immix Biopharma?

Summary

How does Compugen compare to Olema Pharmaceuticals?

Summary

How does Compugen compare to Rigel Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEN vs. The Competition

Compugen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compugen (CGEN) Competitors

CGEN vs. SLDB, WVE, IMMX, OLMA, and RIGL

How does Compugen compare to Solid Biosciences?

Which has better valuation and earnings, SLDB or CGEN?

Do insiders & institutionals hold more shares of SLDB or CGEN?

Do analysts recommend SLDB or CGEN?

Which has more volatility & risk, SLDB or CGEN?

Does the media favor SLDB or CGEN?

Is SLDB or CGEN more profitable?

Summary

How does Compugen compare to WAVE Life Sciences?

Does the media refer more to CGEN or WVE?

Which has more volatility & risk, CGEN or WVE?

Which has stronger valuation & earnings, CGEN or WVE?

Do insiders and institutionals have more ownership in CGEN or WVE?

Is CGEN or WVE more profitable?

Do analysts rate CGEN or WVE?

Summary

How does Compugen compare to Immix Biopharma?

Do institutionals & insiders have more ownership in CGEN or IMMX?

Do analysts rate CGEN or IMMX?

Which has more volatility and risk, CGEN or IMMX?

Is CGEN or IMMX more profitable?

Which has better earnings and valuation, CGEN or IMMX?

Does the media refer more to CGEN or IMMX?

Summary

How does Compugen compare to Olema Pharmaceuticals?

Is CGEN or OLMA more profitable?

Does the media favor CGEN or OLMA?

Which has more risk & volatility, CGEN or OLMA?

Which has preferable earnings & valuation, CGEN or OLMA?

Do analysts rate CGEN or OLMA?

Do insiders & institutionals believe in CGEN or OLMA?

Summary

How does Compugen compare to Rigel Pharmaceuticals?

Which has more volatility & risk, CGEN or RIGL?

Do analysts prefer CGEN or RIGL?

Is CGEN or RIGL more profitable?

Do institutionals & insiders hold more shares of CGEN or RIGL?

Does the media favor CGEN or RIGL?

Which has higher valuation & earnings, CGEN or RIGL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEN vs. The Competition

Compugen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools